• FDA approves Sandoz's biosimilar for Humira

    FDA approval of generic pharmaceutical maker Sandoz's Hyrimoz injection, a biosimilar for Humira, has the potential to "to expand access for millions," according to a March 21 news release.
  • Cancer drug trial halted after patient death

    The FDA placed a clinical hold on drug research conducted by Athenex, a biotech company based in Buffalo, N.Y., after a patient died during a phase one trial, the company said March 20. 
  • The 5 drugs recommended to treat C. auris

    As the U.S. reports a rise in Candida auris cases, which spreads rapidly in healthcare sites, there are five drugs recommended to treat the fungus infections, according to the CDC. 
  • California, Civica partner to manufacture insulin, cap costs

    California has entered a 10-year contract with nonprofit drugmaker Civica Rx to manufacture insulin and cap costs at $30 per vial, Gov. Gavin Newsom announced during a March 18 press conference. 
  • Wyoming bans abortion pills ahead of federal ruling

    Mifepristone, which was approved by the FDA in 2000 for use in ending early term pregnancies, has been banned by Wyoming Gov. Mark Gordon ahead of a federal ruling on the drug pending in a Texas court. 
  • States take aim at EpiPen costs

    At least five states have introduced legislation this year to cap patients' out-of-pocket costs for EpiPens and other generic epinephrine autoinjectors. 
  • Amgen to lay off 450

    Amgen, a drugmaker based in Thousand Oaks, Calif., will lay off 450 people — 2 percent of its workforce — with many separations occurring by May 26, according to a statement shared with Becker's. 
  • 5 common complaints from pharmacy workers

    Working conditions ranked highest among common negative experiences that pharmacy employees face, according to a workplace and well-being report. 
  • 4 cancer drugs in short supply, some resupply dates in summer

    At least four oncology drugs are in shortage, and some drugmakers don't expect supply levels to recover until mid-2023. 
  • Shortage of prostate cancer drug worries physicians

    The shortage of a drug approved just shy of one year ago by the FDA to treat prostate cancer is now in limited supply, concerning some physicians.
  • 4.2M of Pfizer's prescription Nurtec units packaged incorrectly

    More than 4 million packets of Pfizer's Nurtec, a migraine prescription drug, need a fix because the container is not child resistant, the U.S. Consumer Product Safety Commission said March 16.
  • FDA seeks comments on draft guidance for local anesthetic drugs

    Amid the ongoing shortage of local anesthetic drugs, the FDA has drafted new guidance for drugmakers, which could eventually help curb the supply issues.
  • Michigan Medicine, 2 other systems to deploy prescriptions with new drones

    Michigan Medicine will use Zipline's new drones to deliver prescriptions to patients' doors, which will "more than double the number of prescriptions it fills each year through its existing in-house pharmacy," the Ann Arbor-based system said March 15. 
  • 4,980 matches made for pharmacy residency programs

    As the number of pharmacy residency program spots grow year over year, 4,980 people matched with 2,162 programs in the U.S., the American Society of Health-System Pharmacists said March 15. 
  • 4 pressing drug shortages: ASHP

    Weeks after a U.S. drugmaker closed up shop, the American Society of Health-System Pharmacists marked four drugs for being in key shortages. Three are connected to the shutdown of Gurnee, Ill.-based Akorn Operating Co.
  • FDA issues warning to ElectRx over unapproved drugs

    ElectRx has been issued a warning from the FDA after the agency found it in violation of distributing unauthorized, misbranded drugs. 
  • Novel drug developed by Auburn U researchers aims to curb Alzheimer's disease

    A compound that may help prevent early onset of Alzheimer's disease in some people is being developed by researchers at Auburn (Ala.) University. 
  • 16 drugs vulnerable to shortages after US drug company closed

    Sixteen drugs have a high risk of supply disruption after an Illinois drugmaker ceased all operations in February, according to a March 15 report from the End Drug Shortages Alliance. 
  • FDA flags J&J's COVID-19 vaccine for myocarditis, pericarditis risk

    The FDA updated its fact sheet for healthcare providers about Johnson & Johnson's COVID-19 vaccine to include warnings of myocarditis and pericarditis. 
  • US to fine drugmakers over price hikes for 27 meds

    The Biden administration said March 15 it will fine pharmaceutical companies over 27 drug prices that rose faster than the inflation rate. 

Featured Whitepapers

Featured Webinars